JP2016501230A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501230A5
JP2016501230A5 JP2015545438A JP2015545438A JP2016501230A5 JP 2016501230 A5 JP2016501230 A5 JP 2016501230A5 JP 2015545438 A JP2015545438 A JP 2015545438A JP 2015545438 A JP2015545438 A JP 2015545438A JP 2016501230 A5 JP2016501230 A5 JP 2016501230A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antibody
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015545438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501230A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/072243 external-priority patent/WO2014085596A1/en
Publication of JP2016501230A publication Critical patent/JP2016501230A/ja
Publication of JP2016501230A5 publication Critical patent/JP2016501230A5/ja
Pending legal-status Critical Current

Links

JP2015545438A 2012-11-29 2013-11-27 活性化プロテインC(aPC)に対するモノクローナル抗体 Pending JP2016501230A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261731294P 2012-11-29 2012-11-29
US61/731,294 2012-11-29
US201361786472P 2013-03-15 2013-03-15
US61/786,472 2013-03-15
PCT/US2013/072243 WO2014085596A1 (en) 2012-11-29 2013-11-27 MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC)

Publications (2)

Publication Number Publication Date
JP2016501230A JP2016501230A (ja) 2016-01-18
JP2016501230A5 true JP2016501230A5 (enExample) 2017-01-12

Family

ID=50828462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545438A Pending JP2016501230A (ja) 2012-11-29 2013-11-27 活性化プロテインC(aPC)に対するモノクローナル抗体

Country Status (18)

Country Link
US (1) US20150307625A1 (enExample)
EP (1) EP2925351A4 (enExample)
JP (1) JP2016501230A (enExample)
KR (1) KR20150088869A (enExample)
CN (1) CN104812402A (enExample)
AR (1) AR093671A1 (enExample)
AU (1) AU2013352159A1 (enExample)
BR (1) BR112015012414A2 (enExample)
CA (1) CA2892750A1 (enExample)
HK (1) HK1212896A1 (enExample)
IL (1) IL238658A0 (enExample)
MX (1) MX2015006424A (enExample)
RU (1) RU2015125349A (enExample)
SG (1) SG11201503719WA (enExample)
TW (1) TW201429992A (enExample)
UY (1) UY35154A (enExample)
WO (1) WO2014085596A1 (enExample)
ZA (1) ZA201504659B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087391A1 (en) * 2015-11-17 2017-05-26 Bayer Healthcare, Llc Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof
EP3831843A1 (en) * 2019-12-08 2021-06-09 Royal College Of Surgeons In Ireland A hemostatic agent and uses thereof
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
CN116496394B (zh) * 2022-01-26 2024-07-23 东莞市朋志生物科技有限公司 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒
US20250163183A1 (en) * 2022-03-04 2025-05-22 Coagulant Therapeutics Corporation Camelid antibodies against activated protein c and uses thereof
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用
AU2024252640A1 (en) 2023-04-07 2025-10-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
DE69735421T2 (de) * 1996-04-24 2006-10-19 The Regents Of The University Of Michigan, Ann Arbor Gegen inaktivierung resistenter faktor viii
US6989241B2 (en) * 2000-10-02 2006-01-24 Oklahoma Medical Research Foundation Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US20030203355A1 (en) * 2002-04-24 2003-10-30 Los Alamos National Laboratory Fluorobodies: binding ligands with intrinsic fluorescence
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
WO2006017538A2 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
AU2005318171B2 (en) * 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
US7939637B2 (en) * 2005-12-13 2011-05-10 Medimmune Limited Insulin-like growth factor antibodies and uses thereof
US8039597B2 (en) * 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素(sclerostin)抗體組合物及使用方法
WO2009055669A2 (en) * 2007-10-26 2009-04-30 Oklahoma Medical Research Foundation Monoclonal antibodies against activated and unactivated protein c
GB0903151D0 (en) * 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB201011771D0 (en) * 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
EP2640421A4 (en) * 2010-11-16 2014-05-28 Medimmune Llc THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES
US8440797B2 (en) * 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Similar Documents

Publication Publication Date Title
JP2016501230A5 (enExample)
RU2015125349A (ru) МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС)
JP2022031635A5 (enExample)
JP2020039360A5 (enExample)
JP2018510617A5 (enExample)
JP2015522252A5 (enExample)
JP2019515027A5 (enExample)
RU2018125515A (ru) Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2011519571A5 (enExample)
JP2017071606A5 (enExample)
JP2020514277A5 (enExample)
JP2019522961A5 (enExample)
RU2016129113A (ru) Антитела к pd-1 собак
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2018502060A5 (enExample)
JP2019527194A5 (enExample)
JP2011509245A5 (enExample)
JP2012519712A5 (enExample)
HRP20220918T1 (hr) Anti-transtiretinska antitijela
JP2017531642A5 (enExample)
JP2018509889A5 (enExample)
JP2019525728A5 (enExample)
JP2013539352A5 (enExample)
JP2016507555A5 (enExample)
HRP20200846T1 (hr) Anti-il-33 antitijela i njihove primjene